Yada Kanjanapan

1.1k total citations · 1 hit paper
31 papers, 802 citations indexed

About

Yada Kanjanapan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yada Kanjanapan has authored 31 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Yada Kanjanapan's work include Cancer Immunotherapy and Biomarkers (13 papers), Cancer Genomics and Diagnostics (6 papers) and Ovarian cancer diagnosis and treatment (4 papers). Yada Kanjanapan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Cancer Genomics and Diagnostics (6 papers) and Ovarian cancer diagnosis and treatment (4 papers). Yada Kanjanapan collaborates with scholars based in Australia, Canada and United States. Yada Kanjanapan's co-authors include Philippe L. Bédard, Razelle Kurzrock, Édith Borcoman, Stéphane Champiat, Vincent Servois, Sanjay Goel, Christophe Le Tourneau, Shotaro Kato, Desmond Yip and Nicholas Farinola and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Yada Kanjanapan

29 papers receiving 792 citations

Hit Papers

Novel patterns of response under immunotherapy 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Novel patterns of response under immunotherapy
    2019 354 citations Édith Borcoman, Yada Kanjanapan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yada Kanjanapan Australia 12 583 273 154 108 100 31 802
Pedro Nazareth Aguiar Brazil 13 584 1.0× 428 1.6× 122 0.8× 120 1.1× 98 1.0× 73 861
Anna Kondic United States 8 543 0.9× 160 0.6× 213 1.4× 64 0.6× 84 0.8× 18 734
Meredith K. Chuk United States 14 429 0.7× 260 1.0× 133 0.9× 116 1.1× 175 1.8× 29 858
Oyewale O. Abidoye United States 13 451 0.8× 221 0.8× 103 0.7× 77 0.7× 143 1.4× 24 657
Elisa Zanardi Italy 16 355 0.6× 420 1.5× 79 0.5× 170 1.6× 177 1.8× 56 785
Donnah Jones United States 12 280 0.5× 221 0.8× 177 1.1× 87 0.8× 166 1.7× 14 740
Aaron Weitzman United States 15 329 0.6× 259 0.9× 58 0.4× 83 0.8× 181 1.8× 38 1.2k
Anastasios Dimou United States 16 481 0.8× 311 1.1× 56 0.4× 115 1.1× 201 2.0× 67 800
Giovanni M. Bariani Brazil 12 443 0.8× 201 0.7× 93 0.6× 132 1.2× 112 1.1× 32 839
Sven Gogov Switzerland 12 351 0.6× 409 1.5× 86 0.6× 145 1.3× 294 2.9× 25 804

Countries citing papers authored by Yada Kanjanapan

Since Specialization
Citations

This map shows the geographic impact of Yada Kanjanapan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yada Kanjanapan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yada Kanjanapan more than expected).

Fields of papers citing papers by Yada Kanjanapan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yada Kanjanapan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yada Kanjanapan. The network helps show where Yada Kanjanapan may publish in the future.

Co-authorship network of co-authors of Yada Kanjanapan

This figure shows the co-authorship network connecting the top 25 collaborators of Yada Kanjanapan. A scholar is included among the top collaborators of Yada Kanjanapan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yada Kanjanapan. Yada Kanjanapan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kanjanapan, Yada, et al.. (2024). Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors. Clinical Breast Cancer. 25(2). e159–e169.e2. 3 indexed citations
2.
Hicks, Sarah M., Teresa Neeman, Philip Choi, et al.. (2024). Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population. Asia-Pacific Journal of Clinical Oncology. 20(3). 379–385. 1 indexed citations
3.
Fadia, Mitali, et al.. (2024). Cancer metastasis to the upper gastrointestinal tract—a case series. Journal of Gastrointestinal Oncology. 15(6). 2728–2734.
4.
Kanjanapan, Yada, et al.. (2023). Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting. Technology in Cancer Research & Treatment. 22. 2223951017–2223951017.
5.
Kanjanapan, Yada, April A. N. Rose, Daniel Vilarim Araújo, et al.. (2021). Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma. Journal of Investigative Dermatology. 141(10). 2470–2479. 1 indexed citations
6.
Cunningham, Morven, Marco Iafolla, Yada Kanjanapan, et al.. (2021). Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLoS ONE. 16(6). e0253070–e0253070. 25 indexed citations
7.
Kanjanapan, Yada, Prunella Blinman, Craig Underhill, et al.. (2021). Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours. Internal Medicine Journal. 51(6). 955–959. 5 indexed citations
8.
Kanjanapan, Yada, Sheau Wen Lok, Peter Gibbs, et al.. (2020). Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. Breast Cancer Research and Treatment. 184(1). 87–95. 3 indexed citations
9.
Kanjanapan, Yada & Desmond Yip. (2020). Considerations for cancer immunotherapy during theCOVID‐19 pandemic. The Medical Journal of Australia. 213(9). 390–390. 2 indexed citations
10.
Borcoman, Édith, Yada Kanjanapan, Stéphane Champiat, et al.. (2019). Novel patterns of response under immunotherapy. Annals of Oncology. 30(3). 385–396. 354 indexed citations breakdown →
11.
Kanjanapan, Yada, Daphne Day, Marcus O. Butler, et al.. (2018). Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. European Journal of Cancer. 107. 1–7. 51 indexed citations
12.
Kanjanapan, Yada, Daphne Day, Lisa Wang, et al.. (2018). Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.. Journal of Clinical Oncology. 36(15_suppl). 3063–3063. 5 indexed citations
13.
Lheureux, Stéphanie, Julia V. Burnier, Qian Tan, et al.. (2017). Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. Journal of Clinical Oncology. 35(15_suppl). 5522–5522. 6 indexed citations
14.
Kanjanapan, Yada, Siddhartha Deb, Richard J. Young, et al.. (2017). Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. Clinical and Translational Radiation Oncology. 2. 53–58. 8 indexed citations
15.
Kanjanapan, Yada, Stéphanie Lheureux, Taymaa May, et al.. (2017). Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.. Journal of Clinical Oncology. 35(15_suppl). TPS5608–TPS5608. 2 indexed citations
16.
Quek, Richard, Mohamad Farid, Yada Kanjanapan, et al.. (2016). Prognostic significance ofKITexon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor. Asia-Pacific Journal of Clinical Oncology. 13(3). 115–124. 10 indexed citations
17.
Lee, Chee Khoon, David Goldstein, Emma Gibbs, et al.. (2015). Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer. 51(7). 852–860. 22 indexed citations
18.
Kanjanapan, Yada, et al.. (2015). The Challenge of Managing Adrenocortical Carcinoma: Two Case Studies. ANU Open Research (Australian National University). 2(3). 175–184. 1 indexed citations
19.
Farinola, Nicholas & Yada Kanjanapan. (2013). Denosumab‐induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Internal Medicine Journal. 43(11). 1243–1246. 30 indexed citations
20.
Ye, Miao, Pek Siew Lim, Yada Kanjanapan, et al.. (2007). Folic Acid Prevents and Partially Reverses Glucocorticoid-Induced Hypertension in the Rat. American Journal of Hypertension. 20(3). 304–310. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pedro Nazareth Aguiar Breakdown of academic impact, for papers by Anna Kondic Breakdown of academic impact, for papers by Meredith K. Chuk Breakdown of academic impact, for papers by Oyewale O. Abidoye Breakdown of academic impact, for papers by Elisa Zanardi Breakdown of academic impact, for papers by Donnah Jones Breakdown of academic impact, for papers by Aaron Weitzman Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Giovanni M. Bariani Breakdown of academic impact, for papers by Sven Gogov
Rankless by CCL
2026